<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002370</url>
  </required_header>
  <id_info>
    <org_study_id>254B</org_study_id>
    <nct_id>NCT00002370</nct_id>
  </id_info>
  <brief_title>Study of Itraconazole in Patients With Advanced HIV Infection</brief_title>
  <official_title>Pharmacokinetics Study of Intravenous Itraconazole Followed by Oral Dosing at 200 Mg Twice Daily in Patients With Advanced HIV Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen, LP</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      To demonstrate a dosage regimen for intravenous itraconazole that produces a plasma&#xD;
      concentration range comparable to that obtained after currently used oral dosages of&#xD;
      itraconazole oral solution; and to obtain preliminary safety data in patients with advanced&#xD;
      HIV disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will receive intravenous itraconazole solution twice daily for 2 days and then once&#xD;
      daily for five additional days. Patients then randomized to receive twice-daily or once-daily&#xD;
      itraconazole oral solution for an additional 28 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>36</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Itraconazole</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
        Antiretroviral therapy providing patient has already been on a stable, unchanged regimen&#xD;
        for 8 weeks prior to study entry.&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  Documented HIV infection.&#xD;
&#xD;
          -  CD4 lymphocyte count &lt; 300 cells/mm3.&#xD;
&#xD;
          -  No clinically significant abnormalities, elicited by history and physical examination.&#xD;
&#xD;
          -  No clinically significant abnormalities in blood count, biochemical profile, or&#xD;
             urinalysis within 2 weeks of study entry.&#xD;
&#xD;
          -  Negative urine screening.&#xD;
&#xD;
          -  No clinically significant abnormalities of electrocardiogram.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
        Antiretroviral therapy providing patient has been on a stable, unchanged regimen for 8&#xD;
        weeks prior to study entry.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following symptoms and conditions are excluded:&#xD;
&#xD;
          -  Acute opportunistic infection or other significant concurrent illness that would&#xD;
             preclude participation for the required 36 days.&#xD;
&#xD;
          -  Unable to swallow oral solution.&#xD;
&#xD;
          -  Obesity greater than 25% of ideal body weight.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Rifampin.&#xD;
&#xD;
          -  Rifabutin.&#xD;
&#xD;
          -  Phenobarbital.&#xD;
&#xD;
          -  Phenytoin.&#xD;
&#xD;
          -  Carbamazepine.&#xD;
&#xD;
          -  Digoxin.&#xD;
&#xD;
          -  Warfarin.&#xD;
&#xD;
          -  Midazolam.&#xD;
&#xD;
          -  Triazolam.&#xD;
&#xD;
          -  Terfenadine.&#xD;
&#xD;
          -  Astemizole.&#xD;
&#xD;
          -  Cisapride.&#xD;
&#xD;
          -  H2 blockers.&#xD;
&#xD;
          -  Omeprazole.&#xD;
&#xD;
          -  Continual antacids.&#xD;
&#xD;
          -  Didanosine.&#xD;
&#xD;
          -  Any medication known to affect absorption, metabolism or excretion of imidazole or&#xD;
             azole compounds.&#xD;
&#xD;
        Patients with the following prior symptoms and conditions are excluded:&#xD;
&#xD;
          -  Previous hypersensitivity to azole antifungals.&#xD;
&#xD;
          -  History of surgical procedure that may interfere with absorption of itraconazole.&#xD;
&#xD;
          -  History of significant blood loss in the previous 30 days.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
        Excluded within 15 days prior to study entry:&#xD;
&#xD;
          -  Rifampin.&#xD;
&#xD;
          -  Rifabutin.&#xD;
&#xD;
          -  Phenobarbital.&#xD;
&#xD;
          -  Phenytoin.&#xD;
&#xD;
          -  Carbamazepine.&#xD;
&#xD;
          -  Digoxin.&#xD;
&#xD;
          -  Warfarin.&#xD;
&#xD;
          -  Midazolam.&#xD;
&#xD;
          -  Triazolam.&#xD;
&#xD;
        Excluded within 8 weeks prior to study entry:&#xD;
&#xD;
          -  Change in antiretroviral therapy.&#xD;
&#xD;
        Risk Behavior:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
        Patients who chew tobacco or regularly smoke more than 10 cigarettes per day.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Erie County Med Ctr / Pharmacy D</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 1997</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Itraconazole</keyword>
  <keyword>Administration, Oral</keyword>
  <keyword>Antifungal Agents</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>Drug Administration Schedule</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Itraconazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

